Compare Stocks: CMPS, ATAI, and PSIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
CMPS Compass Pathways	$9.01 -1.2%	$11.89	$4.88 ▼ $15.87	$1.29B	2.43	3.80 million shs	2.62 million shs
PSIL AdvisorShares Psychedelics ETF	$19.23 -0.9%	$21.90	$15.63 ▼ $27.02	$41.34M	0.98	32,244 shs	20,506 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	0.00%	+1.24%	+69.75%
CMPS Compass Pathways	0.00%	+4.65%	-22.46%	-33.01%	+53.75%
PSIL AdvisorShares Psychedelics ETF	0.00%	-0.83%	-6.38%	-23.90%	+2.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.35	$7.29	$3.27 ▼ $7.45	$2.73B	1.54	13.29 million shs	N/A
CMPS Compass Pathways	$9.01 -1.2%	$11.89	$4.88 ▼ $15.87	$1.29B	2.43	3.80 million shs	2.62 million shs
PSIL AdvisorShares Psychedelics ETF	$19.23 -0.9%	$21.90	$15.63 ▼ $27.02	$41.34M	0.98	32,244 shs	20,506 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	0.00%	+1.24%	+69.75%
CMPS Compass Pathways	0.00%	+4.65%	-22.46%	-33.01%	+53.75%
PSIL AdvisorShares Psychedelics ETF	0.00%	-0.83%	-6.38%	-23.90%	+2.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.07	Hold	$10.56	43.62% Upside
CMPS Compass Pathways	2.88	Moderate Buy	$23.14	156.86% Upside
PSIL AdvisorShares Psychedelics ETF	2.72	Moderate Buy	$19.23	N/A

Current Analyst Ratings Breakdown

Latest CMPS, ATAI, and PSIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/9/2026	CMPS Compass Pathways	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/9/2026	CMPS Compass Pathways	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
11/4/2026	CMPS Compass Pathways	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
11/4/2026	CMPS Compass Pathways	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$13.00 ➝ $10.00
11/3/2026	CMPS Compass Pathways	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$20.00
11/3/2026	CMPS Compass Pathways	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$25.00
10/15/2026	CMPS Compass Pathways	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/22/2026	ATAI Atai Beckley	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Dropped Coverage	Neutral
9/9/2026	CMPS Compass Pathways	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Market Perform

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	666.46	N/A	N/A	$0.69 per share	10.65
CMPS Compass Pathways	N/A	N/A	N/A	N/A	$1.00 per share	N/A
PSIL AdvisorShares Psychedelics ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	N/A
CMPS Compass Pathways	-$287.86M	-$3.49	N/A	N/A	N/A	N/A	-18.03%	-5.11%	N/A
PSIL AdvisorShares Psychedelics ETF	N/A	N/A	38.20	N/A	N/A	N/A	N/A	N/A	N/A

Latest CMPS, ATAI, and PSIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
11/3/2026	Q3 2026	CMPS Compass Pathways	-$0.39	-$0.31	+$0.08	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
PSIL AdvisorShares Psychedelics ETF	$1.68	8.74%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
CMPS Compass Pathways	0.35	1.50	1.50
PSIL AdvisorShares Psychedelics ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
CMPS Compass Pathways	46.19%
PSIL AdvisorShares Psychedelics ETF	N/A

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
CMPS Compass Pathways	2.82%
PSIL AdvisorShares Psychedelics ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
CMPS Compass Pathways	156	141.71 million	137.71 million	Optionable
PSIL AdvisorShares Psychedelics ETF	N/A	2.15 million	N/A	Not Optionable

CMPS, ATAI, and PSIL Headlines

Recent News About These Companies

Pacifica Silver Intersects 5.04 m of 8.72 g/t Au and 49 g/t Ag in 500 m Step-Out, Outlining New High-Grade Shoot on Central Vein at Claudia

October 28, 2026 | newsfilecorp.comN

変わり種ETFの世界－－政治家の財布から海の運賃まで

October 14, 2026 | note.comN

(PSIL) AdvisorShares Psychedelics ETF

September 1, 2026 | sa.investing.com

Pacifica Silver Identifies New High-Grade Aguilarena Mineralized Shoot at Claudia Project; Provides Exploration Update

July 28, 2026 | newsfilecorp.comN

Pacifica Silver Reports Strong Gold-Silver Intercepts at Claudia Project and Extends Justina Vein to 600 Metres in Strike Length

June 11, 2026 | newsfilecorp.comN

Drilldown: AdvisorShares psychedelics ETF

May 28, 2026 | msn.com

Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging

April 20, 2026 | wsj.com

Psychedelic stocks soar as Trump signs order to ease access

April 20, 2026 | msn.com

Save this psychedelic stock watchlist after Trump’s latest executive order

April 20, 2026 | msn.com

Pacifica Silver Reports Initial Phase II Drill Results at Claudia with Multiple High-Grade Intercepts at the AguilareÃ±a Area

April 14, 2026 | newsfilecorp.comN

Pacifica Silver Announces Adoption of Semi-Annual Reporting

April 9, 2026 | newsfilecorp.comN

9 best psychedelic stocks to buy in 2026

March 24, 2026 | msn.com

Pacifica Silver Reports Additional Drill Results at Claudia with Multiple High-Grade Silver-Gold Intercepts at the AguilareÃ±a Area

February 18, 2026 | newsfilecorp.comN

Pacifica Silver Makes New High-Grade Discovery at Claudia with 3.53 g/t Au and 460 g/t Ag over 2.10 m from Justina Vein

February 9, 2026 | newsfilecorp.comN

Pacifica Silver Announces Closing of Upsized Brokered Offering

January 23, 2026 | newsfilecorp.comN

Pacifica Silver to Launch 12,000 m Phase II Drill Program at the Claudia Silver-Gold Project

January 12, 2026 | newsfilecorp.comN

Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?

December 24, 2025 | msn.com

Groovy: Psychedelics ETF PSIL a Top-5 Active ETF YTD

December 22, 2025 | etftrends.comE

Optimism flows from pot to psychedelics: Atai Beckley, Supernus stocks rise after analyst flags positive tailwinds from Trump’s marijuana order

December 19, 2025 | msn.com

Pacifica Silver Drills 6.35 m of 2.94 g/t Au and 313 g/t Ag, Including 0.85 m of 9.27 g/t Au and 1,905 g/t Ag; Confirms Northern Extension of the AguilareÃ±a Vein at the Claudia Project

December 15, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, ATAI, and PSIL Company Descriptions

Atai Beckley NASDAQ:ATAI

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Compass Pathways NASDAQ:CMPS

$9.01 -0.11 (-1.21%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$8.93 -0.08 (-0.93%)

As of 11/13/2026 07:59 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

AdvisorShares Psychedelics ETF NYSEARCA:PSIL

$19.23 -0.17 (-0.88%)

Closing price 11/13/2026 04:10 PM Eastern

Extended Trading

$19.21 -0.02 (-0.10%)

As of 11/13/2026 07:30 PM Eastern

The AdvisorShares Psychedelics ETF (PSIL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed to provide exposure to the emerging global psychedelics industry. PSIL was launched on Sep 15, 2021 and is managed by AdvisorShares.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPS, ATAI, and PSIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPS, ATAI, and PSIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPS, ATAI, and PSIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, ATAI, and PSIL Company Descriptions

Atai Beckley NASDAQ:ATAI

Compass Pathways NASDAQ:CMPS

AdvisorShares Psychedelics ETF NYSEARCA:PSIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPS, ATAI, and PSIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPS, ATAI, and PSIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPS, ATAI, and PSIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, ATAI, and PSIL Company Descriptions

Atai Beckley NASDAQ:ATAI

Compass Pathways NASDAQ:CMPS

AdvisorShares Psychedelics ETF NYSEARCA:PSIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools